About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Erdafitinib Effective for Advanced Bladder Cancer Patients With Certain Gene Mutations

by Ramya Rachamanti on July 25, 2019 at 5:19 PM
Erdafitinib Effective for Advanced Bladder Cancer Patients With Certain Gene Mutations

Metastatic bladder cancer patients with mutations in FGFR3 gene had 40% overall response rate (ORR) with good tolerance after getting treated with Erdafitinib in an international Phase II trial led by the University of Texas MD Anderson Cancer Center.

The trial results, published in the New England Journal of Medicine, led to approval of erdafitinib in April by the Food and Drug Administration (FDA), making it the first targeted therapy approved for treating patients with advanced bladder cancer.

Advertisement


The oral targeted therapy also achieved a 59% ORR in patients for whom immunotherapy had previously failed, indicating this may be a viable option for these patients in need of alternative treatments. The findings were first reported at the 2018 American Society of Clinical Oncology Annual Meeting by principal investigator Arlene Siefker-Radtke, M.D., professor of Genitourinary Medical Oncology.

"Patients have been in desperate need for alternative strategies, especially when a large number of patients cannot tolerate the current standards of care," said Siefker-Radtke. "We were very gratified to see a 40% response rate in patients treated on this clinical trial. Not only did it work well in patients with lymph node metastases, but also in patients with high volume and very aggressive disease."
Advertisement

Standard of care for these cancers is cisplatin-based chemotherapy, an aggressive regimen with significant side effects, and this has largely remained unchanged for several decades, explained Siefker-Radtke. Recently, immune checkpoint inhibitors have been approved for the treatment of advanced bladder cancer, but only 15 to 20% of patients see any benefit from these therapies, she said.

"I noticed that I wasn't seeing a great response to immune checkpoint inhibitors in my patients with FGFR3 mutations, which led me to wonder whether this would reflect a group of patients with an unmet need," said Siefker-Radtke. "When we heard about novel agents targeting this pathway, I became quite interested in exploring them in our bladder cancer patients."

Mutations in FGFR3 are present in approximately 15 to 20% of patients with metastatic bladder cancer and up to 35% of patients with other urothelial cancers, such as those of the renal pelvis and ureter. The international trial enrolled 99 patients with metastatic or surgically unresectable urothelial cancer and verified alterations in the FGFR3 gene.

Three patients in the trial had complete responses, or tumor disappearance, and 39 had percent stable disease. Median PFS was 5.5 months and median OS was 13.8 months. Among 22 patients previously treated with immunotherapy, 59% (13) had a partial or complete response.

"With a response rate of over 50% in patients previously treated with immunotherapy, the data suggest treatment with erdafitinib may be preferential for patients with FGFR3 mutations. However, this is preliminary evidence, so we need additional data to confirm this finding," said Siefker-Radtke.

All patients on the trial reported side effects from the therapy, with 21% discontinuing treatment due to adverse events and 67% reporting grade 3 or 4 adverse events. The most common treatment-related side effects were stomatitis (9%), nail dystrophy (6%), and hand-foot syndrome (5%).

Based on the results of the trial, the FDA granted a breakthrough therapy designation to erdafitinib in 2018 and approved the drug in April 2019 for treating patients with locally advanced or metastatic urothelial cancers with mutations in the FGFR2 or FGFR3 genes.

"With the recent approval of erdafitinib for the treatment of patients with FGFR3-mutant urothelial cancers, we now have an additional agent to add to our armamentarium," said Siefker-Radtke. "My hope is we will be able to add this to our treatment strategy, learn how it combines with immunotherapy and how we can use the effects of this drug to improve the survival for all of our bladder cancer patients."

A Phase III trial currently is underway to evaluate the efficacy of erdafitinib relative to chemotherapy or the checkpoint blockade inhibitor pembrolizumab in patients with metastatic urothelial cancer and FGFR3 mutations.



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Clinical Trials News

'Artificial Wombs' In Human Trials Awaits FDA Approval
FDA approval is sought for “artificial womb” clinical trials (mimicking lamb trials) in humans, that can potentially reduce mortality in premature babies.
Injecting Platelets Could be as Beneficial as Exercising to the Brain
Increasing the levels of platelet-derived factors in the body may lessen the effect of age-related degenerative changes and cognitive impairment in the brain.
Engineered Bacteria Offer New Hope for Early Cancer Detection
Constructing bacteria to become drug resistant only when they took up DNA containing cancer-associated changes, could be useful in detecting cancer.
Is Eli Lilly's Drug the Future of Obesity Treatment?
Eli Lilly's Mounjaro may prove an alternative to bariatric surgery, stated clinical trial results.
Made In India 'Liquid Cornea' Will Soon Undergo Human Trial
After achieving an 80 percent success rate in treating animals, Indian doctors plan to advance to human trials for the liquid cornea.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Erdafitinib Effective for Advanced Bladder Cancer Patients With Certain Gene Mutations Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests